Mohammad Abdi1,2, Rizgar Rahbari3, Zahed Khatooni2, Nima Naseri4, Adel Najafi5, Iraj Khodadadi6. 1. Cellular and Molecular Research Center, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. 2. Department of Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Kurdistan, Iran. 3. Department of Pathology and Medical Laboratory Sciences, Faculty of Para Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. 4. Clinical Laboratory of Be'sat Hospital, Sanandaj, Iran. 5. Department of Microbiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Department of Biochemistry and Nutrition, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Abstract
BACKGROUND: CD4(+) cell count, the common HIV infection screening test, is costly and unable to differentiate HIV monoinfection from its concurrent infection with hepatitis B or C virus. We aimed to ascertain diagnostic value of serum adenosine deaminase (ADA) activity as a useful tool to differentiate HIV mono- and co-infection. METHODS: Blood samples were collected from 30 HIV-HBV and 30 HIV-HCV coinfected patients, 33 HIV positive subjects, and 72 controls. CD4(+) cell count, serum total ADA (tADA), and ADA1, and ADA2 isoenzyme activities were determined and their sensitivity and specificity were computed. RESULTS: tADA and ADA2 activities were significantly higher and CD4(+) counts were markedly lower in all patients compared with controls. Strong inverse agreements between CD4(+) cell counts and both tADA and ADA2 activities were observed. Serum tADA and ADA1 activities showed the highest specificity and the highest sensitivity, respectively, for differentiating HIV monoinfection from HIV-HBV and HIV-HCV coinfections. CONCLUSIONS: We showed strong agreement and correlation between CD4(+) cell count and ADA enzyme activity. Based on high ADA sensitivity and specificity, it is concluded that determination of ADA activity might be a novel diagnostic tool to distinguish of HIV monoinfection from its coinfection with HBV or HCV.
BACKGROUND:CD4(+) cell count, the common HIV infection screening test, is costly and unable to differentiate HIV monoinfection from its concurrent infection with hepatitis B or C virus. We aimed to ascertain diagnostic value of serum adenosine deaminase (ADA) activity as a useful tool to differentiate HIV mono- and co-infection. METHODS: Blood samples were collected from 30 HIV-HBV and 30 HIV-HCV coinfectedpatients, 33 HIV positive subjects, and 72 controls. CD4(+) cell count, serum total ADA (tADA), and ADA1, and ADA2 isoenzyme activities were determined and their sensitivity and specificity were computed. RESULTS:tADA and ADA2 activities were significantly higher and CD4(+) counts were markedly lower in all patients compared with controls. Strong inverse agreements between CD4(+) cell counts and both tADA and ADA2 activities were observed. Serum tADA and ADA1 activities showed the highest specificity and the highest sensitivity, respectively, for differentiating HIV monoinfection from HIV-HBV and HIV-HCV coinfections. CONCLUSIONS: We showed strong agreement and correlation between CD4(+) cell count and ADA enzyme activity. Based on high ADA sensitivity and specificity, it is concluded that determination of ADA activity might be a novel diagnostic tool to distinguish of HIV monoinfection from its coinfection with HBV or HCV.
Authors: Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward Journal: MMWR Recomm Rep Date: 2008-09-19
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: J G Niedzwicki; N M Kouttab; K H Mayer; C C Carpenter; R E Parks; E Abushanab; D R Abernethy Journal: J Acquir Immune Defic Syndr (1988) Date: 1991
Authors: Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal Journal: Purinergic Signal Date: 2018-08-10 Impact factor: 3.765